MAR of each statin, separated by perspective
| Level of risk parameters of each statin19–22 | MAR of each statin for each benefit criterion | ||||||
|---|---|---|---|---|---|---|---|
| Statins | Myalgia (%) | Hepatotoxicity (%) | Perspective | Myalgia (%) | Hepatotoxicity (%) | ||
| Stroke | MI | Stroke | MI | ||||
| Atorvastatin | 5.60 | 1.25 | Patients* | 15.83 | 19.07 | 2.11 | 2.55 |
| Experts† | 20.21 | 23.12 | 3.38 | 3.87 | |||
| PM‡ | 28.09 | 36.69 | 3.34 | 4.37 | |||
| Fluvastatin | 4.40 | 2.55 | Patients* | 13.30 | 21.58 | 1.78§ | 2.88 |
| Experts† | 16.97 | 26.16 | 2.84 | 4.38 | |||
| PM‡ | 23.59 | 41.52 | 2.81 | 4.94 | |||
| Lovastatin | 2.40 | 1.90 | Patients* | 31.00 | 9.04 | 2.62 | 1.21§ |
| Experts† | 25.06 | 10.95 | 4.19 | 1.83§ | |||
| PM‡ | 34.83 | 17.38 | 4.15 | 2.07 | |||
| Pravastatin | 1.00 | 1.20 | Patients* | 8.86 | 11.04 | 1.18§ | 1.47 |
| Experts† | 11.32 | 13.38 | 1.89 | 2.24 | |||
| PM‡ | 15.73 | 21.24 | 1.87 | 2.53 | |||
| Rosuvastatin | 2.80 | 2.20 | Patients* | 6.33 | 18.07 | 0.85§ | 2.41 |
| Experts† | 8.08 | 21.90 | 1.35§ | 3.66 | |||
| PM‡ | 11.23 | 34.76 | 1.34§ | 4.14 | |||
| Simvastatin | 3.70 | 1.00 | Patients* | 15.20 | 13.05 | 2.03 | 1.74 |
| Experts† | 19.40 | 15.82 | 3.24 | 2.65 | |||
| PM‡ | 26.96 | 25.10 | 3.21 | 2.99 | |||
*Patients (N=223).
†Clinical experts (N=63).
‡PMs (N=67).
§Unacceptable risk level.
MAR, maximum acceptable risk; MI, myocardial infarction; PM, policymaker.